Persistent quality of life impairments in differentiated thyroid cancer patients: results from a monitoring programme

被引:71
|
作者
Gamper, Eva-Maria [1 ,2 ]
Wintner, Lisa M. [2 ]
Rodrigues, Margarida [1 ]
Buxbaum, Sabine [1 ]
Nilica, Bernhard [1 ]
Singer, Susanne [3 ]
Giesinger, Johannes M. [4 ]
Holzner, Bernhard [2 ]
Virgolini, Irene [1 ]
机构
[1] Med Univ Innsbruck, Dept Nucl Med, A-6020 Innsbruck, Austria
[2] Med Univ Innsbruck, Dept Psychiat & Psychotherapy, A-6020 Innsbruck, Austria
[3] Johannes Gutenberg Univ Mainz, Inst Med Biostat Epidemiol & Informat, D-55122 Mainz, Germany
[4] Netherlands Canc Inst, Amsterdam, Netherlands
基金
奥地利科学基金会;
关键词
Differentiated thyroid cancer; Health-related quality of life; Radioiodine remnant ablation; HORMONE WITHDRAWAL; CARCINOMA PATIENTS; PROFILES REGISTRY; SURVIVORS; RADIOIODINE; FATIGUE; DISEASE; POPULATION; ABLATION; THERAPY;
D O I
10.1007/s00259-015-3022-9
中图分类号
R8 [特种医学]; R445 [影像诊断学];
学科分类号
1002 ; 100207 ; 1009 ;
摘要
Purpose Health-related quality of life (HRQOL) in differentiated thyroid cancer (DTC) research has so far received little attention and available results are conflicting. We studied the HRQOL of radioiodine-naive DTC patients in comparison with the general population (GP), investigated the course of HRQOL up to 30 months after radioiodine remnant ablation (RAA) and sought to identify patient characteristics associated with HRQOL. Methods We analysed data from routine HRQOL monitoring at a nuclear medicine department. Between 2005 and 2013, a total of 439 thyroid cancer patients (all histologies) completed the EORTC Quality of Life Questionnaire Core-30 (QLQ-C30) at least once during their treatment at the department. We compared patients' baseline HRQOL scores before RAA with scores from age-matched and sex-matched controls from the Austrian GP. We then determined the course of HRQOL over the 30 months after RAA and assessed the impact of the following clinical variables on HRQOL: method of thyroid-stimulating hormone (TSH) stimulation, histology (papillary vs. follicular) and disease stage. Results A total of 284 patients (mean age 48.3 years, SD 15.0 years; 71.6 % women; 80.7 % papillary type) with a baseline HRQOL assessment before RAA were available. We found clinically meaningful differences in the detriment in patients on almost all domains. These were largest for fatigue (23 points) and role functioning (25 points). Data from 241 patients (mean age 48.6 years, SD 15.9 years; 68.9 % women; 76.3 % papillary type) were included in the longitudinal analysis. Investigating the course of HRQOL, a significant improvement over time was found for role and emotional functioning, fatigue, pain, and dyspnoea. A range of HRQOL scores were improved in patients with exogenous TSH stimulation, but some scores both in patients with exogenous TSH stimulation and in those followed for 30 months, especially fatigue and role functioning, did not reach levels in the GP sample. Conclusion Our results show that the favourable prognosis of DTC does not directly translate into good HRQOL in these patients. Persistent restrictions in regaining their normal daily life in terms of work and leisure highlight the importance of more detailed investigation of DTC patients' wellbeing, support needs, and disease experience.
引用
收藏
页码:1179 / 1188
页数:10
相关论文
共 50 条
  • [1] Persistent quality of life impairments in differentiated thyroid cancer patients: results from a monitoring programme
    Eva-Maria Gamper
    Lisa M. Wintner
    Margarida Rodrigues
    Sabine Buxbaum
    Bernhard Nilica
    Susanne Singer
    Johannes M Giesinger
    Bernhard Holzner
    Irene Virgolini
    European Journal of Nuclear Medicine and Molecular Imaging, 2015, 42 : 1179 - 1188
  • [2] Quality of life in differentiated thyroid cancer
    McIntyre, Charlotte
    Jacques, Thomas
    Palazzo, Fausto
    Farnell, Kate
    Tolley, Neil
    INTERNATIONAL JOURNAL OF SURGERY, 2018, 50 : 133 - 136
  • [3] Editorial: Improving quality of life in patients with differentiated thyroid cancer
    Khafif, Avi Hefetz
    Cohen, Oded
    Dionigi, Gianlorenzo
    FRONTIERS IN ONCOLOGY, 2023, 13
  • [4] Review: Improving quality of life in patients with differentiated thyroid cancer
    Pace-Asciak, Pia
    Russell, Jonathon O.
    Tufano, Ralph P.
    FRONTIERS IN ONCOLOGY, 2023, 13
  • [5] Evaluation of the quality of life in patients followed for differentiated cancer of the thyroid
    Haraj, Nassim Essabah
    Bouri, Hicham
    El Aziz, Siham
    Nani, Samira
    Habti, Noureddine
    Chadli, Asma
    ANNALES D ENDOCRINOLOGIE, 2019, 80 (01) : 26 - 31
  • [6] The effect of neck dissection on quality of life in patients with differentiated thyroid cancer
    Dimov, Rossen S.
    GLAND SURGERY, 2013, 2 (04) : 219 - 226
  • [7] Longitudinal analysis of quality of life in patients treated for differentiated thyroid cancer
    van Velsen, Evert F. S.
    Massolt, Elske T.
    Heersema, Helene
    Kam, Boen L. R.
    van Ginhoven, Tessa M.
    Visser, W. Edward
    Peeters, Robin P.
    EUROPEAN JOURNAL OF ENDOCRINOLOGY, 2019, 181 (06) : 671 - 679
  • [8] Differentiated thyroid cancer in a Swedish county - long-term results and quality of life
    Malterling, Rebecka R.
    Andersson, Roland E.
    Falkmer, Sture
    Falkmer, Ursula
    Nilehn, Eva
    Jarhult, Johannes
    ACTA ONCOLOGICA, 2010, 49 (04) : 454 - 459
  • [9] Thyroid hormone and its metabolites in relation to quality of life in patients treated for differentiated thyroid cancer
    Massolt, E. T.
    van der Windt, M.
    Korevaar, T. I. M.
    Kam, B. L. R.
    Burger, J. W.
    Franssen, G. J. H.
    Lehmphul, I.
    Koehrle, J.
    Visser, W. E.
    Peeters, R. P.
    CLINICAL ENDOCRINOLOGY, 2016, 85 (05) : 781 - 788
  • [10] Quality of Life and Anxiety in Adolescents with Differentiated Thyroid Cancer
    Oren, Asaf
    Benoit, Melissa Anne
    Murphy, Anne
    Schulte, Fiona
    Hamilton, Jill
    JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2012, 97 (10): : E1933 - E1937